TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00492466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Description: dosage and frequency as per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: dosage and frequency as per Biogen Idec protocol
Study: NCT03175783

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fitbit Zip Activity Tracker
Description: Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Zip Activity Tracker
Description: Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.
Study: NCT00091182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT01298596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Electrosurgical Excision Procedure (LEEP)
Description: LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
Study: NCT00898677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sumatriptan
Description: single dose administration of sumatriptan 100 p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: placebo to rizatriptan
Study: NCT00558285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol/glycopyrrolate
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol/glycopyrrolate
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol/glycopyrrolate
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indacaterol
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrrolate
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
Study: NCT00337766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin (DDAVP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04377646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 400 mg at day 1 and day 2, then 400 mg weekly up to 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 400 mg at day 1 and day 2, then 400 mg weekly up to 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine (placebo)
Description: 1 pill at day 1 and day 2, then 1 pill weekly up to 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: 15 mg per day up to 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc (Placebo)
Description: 1 pill per day up to 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc (Placebo)
Description: 1 pill per day up to 2 months
Study: NCT03149783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine HCL
Description: Ropivacaine injected after placement of catheters, then infused during the operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: Placebo
Study: NCT03633383

Intervention type: DEVICE
Intervention: Transcatheter aortic valve
Description: Self-expandable aortic valve prothesis

Intervention type: DEVICE
Intervention: Transcatheter aortic valve
Description: Self-expandable aortic valve prothesis
Study: NCT01217112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg capsules, QDS, PO, 91 days
Study: NCT04231526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 2 cycles of neoadjuvant pembrolizumab (200mg IV every 21 days)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard of care surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Standard of care surgery
Study: NCT02892955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAS
Description: Implantation of HeartMate 3 LVAD to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the MOMENTUM 3 IDE Study.
Study: NCT04044989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Diode laser device was used for photobiomodulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Diode laser device was used for photobiomodulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light-emitting diode (LED)
Description: LED device was used for photobiomodulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light-emitting diode (LED)
Description: LED device was used for photobiomodulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diode laser device was used for placebo effect

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diode laser device was used for placebo effect
Study: NCT02637882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ear plug
Description: The patients will receive the first intervention (ear plug) in the third night (N3) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Eye mask
Description: The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale

Intervention type: OTHER
Group type: OTHER
Intervention: Mixed intervention (ear plug and eye mask)
Description: The patients will receive the intervention (eye mask and ear plug) in the first night (N1) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
Study: NCT04026490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention
Description: The Interventionist will use motivational interviewing skills, assess ethnic and racial microaggressions, and provide support, screen for posttraumatic stress, and, if appropriate, link student to advanced care. The student may meet with the Interventionist several times during the remainder of the school year. These meetings will be approximately 10-30 minutes in length and occur during the school day in a private location determined by the Interventionist. The student may be referred to additional resources as a result of the meetings. The meetings will be documented by the Interventionist using a case management system (in RedCap).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Intervention
Description: In order to compare outcomes contemporaneously, students from waitlisted schools will be asked to complete baseline and follow-up surveys, which will be collected at approximately the same time as in the immediate intervention schools. The data will be captured for analysis at the end of the study. Students will complete intervention following the waitlist period.
Study: NCT01994148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: In this study, laparoscopic intervention will be performed under carbon dioxide pneumoperitoneum (pressure, 10-12 mm Hg; flow volume, 8-10 L/min). A 12-mm trocar will be placed in the umbilicus with use of an open technique and to establish pneumoperitoneum.A 10-mm and a 5-mm trocar will be inserted in the right and left flanks,respectively.
Study: NCT03725488

Intervention type: OTHER
Intervention: Questionnaire
Description: students were involved in the pre-clinical prosthodontic lab. Participation in these labs were mandatory and it involved crown and bridge preparations on typodont models. There were 2 sessions of these labs per week, one for each gender. Each session lasted for 3 hours.~The study was conducted in 2 phases. At the beginning of the first phase of the study, the labs were conducted without any BM for 4 weeks. PSS(perceived stress scale), a standardized and validated, self-reporting international test was used for measuring the level of psychological stress were administered to all participants.

Intervention type: OTHER
Intervention: Questionnaire
Description: students were involved in the pre-clinical prosthodontic lab. Participation in these labs were mandatory and it involved crown and bridge preparations on typodont models. There were 2 sessions of these labs per week, one for each gender. Each session lasted for 3 hours.~The study was conducted in 2 phases. At the beginning of the first phase of the study, the labs were conducted without any BM for 4 weeks. PSS(perceived stress scale), a standardized and validated, self-reporting international test was used for measuring the level of psychological stress were administered to all participants.
Study: NCT02626026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally.
Study: NCT02182193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 capsules charge 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 capsules charge 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBF 1120 drinking solution
Study: NCT00299234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: titration schedule: 0.5 to 1.5 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: titration schedule: 0.5 to 1.5 mg/kg/day
Study: NCT02763384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Study: NCT02693873

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GLA:D Canada (education and neuromuscular exercise program)
Description: EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.~EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions).
Study: NCT01028573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS (Golytely)
Description: 4L consumed evening before colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-ELS (Golytely)
Description: 2L consumed on the evening before and 2L consumed on the morning of Colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miralax mixed with Gatorade
Description: 238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miralax
Description: 1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
Study: NCT01735123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: hydrolyzed vs. nonhydrolyzed infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: hydrolyzed vs. nonhydrolyzed infant formula
Study: NCT01640756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AqueSys Microfistula Implant
Description: Placement of the AqueSys Microfistula Implant in the study eye
Study: NCT03614923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Administered by subcutaneous injection
Study: NCT04358445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium-Rich Artificial Cerebrospinal Fluid
Description: The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
Study: NCT00724347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consonant Identification Training
Description: Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
Study: NCT01176903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: pressurized metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: pressurized metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: pressurized metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: pressurized metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: pressurized metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: pressurized metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: pressurized metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: pressurized metered dose inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: inhalation powder, hard capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pressurized metered dose inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pressurized metered dose inhaler
Study: NCT00889213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Falciform patch and fibrin glue application
Description: Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pancreatic closure
Description: Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
Study: NCT03266250

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: Transthoracic echocardiography of inferior vena cava before spinal anesthesia

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: Transthoracic echocardiography of inferior vena cava before spinal anesthesia
Study: NCT00290823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: 400 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: 400 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6mg or 8mg taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6mg or 8mg taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20 mg tablet taken orally daily
Study: NCT02979535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, SC at Day 0, Months 6 and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, SC at Months 1, 7, and 13

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
Description: 0.5 mL, IM at Day 0 and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
Description: 0.5 mL, IM at Day 0 and Month 6
Study: NCT00505739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg by mouth (PO) Daily x 4 Weeks
Study: NCT02588391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Active)
Description: Online computer games targeting attention, EF, and problem-solving match the child's skill level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Passive)
Description: Online computer games targeting attention, EF, and problem solving are set to a consistent level.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brain Training (Active or Passive)
Description: Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
Study: NCT00748046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 chloride (BAY88-8223)
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
Study: NCT04763122

Intervention type: OTHER
Intervention: not applicable as it is a retrospective study
Description: It is a retrospective study
Study: NCT02662842

Intervention type: DEVICE
Intervention: FlowSmart Infusion Set
Description: Use of set for subcutaneous insulin infusion, with set change every three days.

Intervention type: DEVICE
Intervention: Current Infusion Set
Description: Use of set for subcutaneous insulin infusion, with set change every three days.
Study: NCT04482751

Intervention type: DRUG
Intervention: Corifollitropin alfa
Description: AMH will be measured during ovarian stimulation with corifollitropin alfa
Study: NCT04413890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone vaginal gel
Description: Prostaglandin gel 0.5, 1 or 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal gel
Description: Prostaglandin gel 0.5, 1 or 2 mg
Study: NCT01669122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: 4 mg nicotine lozenge experimental